Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Preventing lead poisoning in young children.

BIBLIOGRAPHIC SOURCE(S)

  • Centers for Disease Control and Prevention (CDC). Preventing lead poisoning in young children. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2005 Aug. 101 p. [139 references]

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Recommendations to health-care providers and community-based health and social service agencies are given below (refer to original guideline document for recommendations for federal, state, and local agencies).

The Centers for Disease Control and Prevention (CDC) recommends that health care providers continue their traditional role of providing anticipatory guidance as part of routine well-child care, assessing risk for exposure to lead, conducting blood lead screening in children, and treating children identified with elevated blood lead levels (BLLs). In addition health-care and social service providers are urged to expand their roles. They should keep abreast of research data that clarify the relationship between lead exposure and neurocognitive development in children. They also can strongly advocate for children and foster lead exposure prevention by helping facilitate implementation of the specific strategic plans to eliminate childhood lead poisoning in their local and state communities. Health-care and social service providers are highly effective child advocates, and their active participation in the process provides the expertise and leadership needed to reach this goal. Health-care and social service providers should:

  1. Provide culturally appropriate education to all pregnant women and to families with young children about the principal sources of lead and ways to reduce exposure.
  2. Target outreach, education, and screening programs to populations with the greatest risk for lead exposure.
  3. Become aware of, and actively support, lead poisoning elimination efforts in the community.
  4. Express concern to federal, state, and local policy and decision makers that children live in a lead-safe environment and actively support legislation and regulatory initiatives. Advocate for lead-safe, affordable housing by supporting appropriate legislation.
  5. Become aware of and comply with lead screening policies issued by Medicaid or state and local health departments.
  6. Ensure training of staff members engaged in housing renovation or rehabilitation in lead-safe work practices.

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Centers for Disease Control and Prevention (CDC). Preventing lead poisoning in young children. Atlanta (GA): Centers for Disease Control and Prevention (CDC); 2005 Aug. 101 p. [139 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2005 Aug

GUIDELINE DEVELOPER(S)

Centers for Disease Control and Prevention - Federal Government Agency [U.S.]
Department of Health and Human Services (U.S.) - Federal Government Agency [U.S.]
Public Health Service (U.S.) - Federal Government Agency [U.S.]

SOURCE(S) OF FUNDING

United States Government

GUIDELINE COMMITTEE

Advisory Committee on Childhood Lead Poisoning

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Primary Authors: Julie L. Gerberding, MD, MPH, Director, Centers for Disease Control and Prevention; Tom Sinks, PhD, Acting Director, National Center for Environmental Health; Jim Rabb, Acting Director, Division of Emergency and Environmental Health Services; Mary Jean Brown, ScD, RN, Chief, Lead Poisoning Prevention Branch

Committee Members: Carla Campbell, MD, MS (Chair) The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Mary Jean Brown, ScD, RN (Executive Secretary) Chief, Lead Poisoning Prevention Branch, National Center for Environmental Health Centers for Disease Control and Prevention, Atlanta, Georgia; William Banner, Jr. MD, PhD, The Children's Hospital at Saint Francis, Tulsa, Oklahoma; Helen J. Binns, MD, MPH*, Children's Memorial Hospital, Chicago, Illinois; Walter S. Handy, Jr., PhD, Cincinnati Health Department, Cincinnati, Ohio; Ing Kang Ho, PhD, University of Mississippi Medical Center, Jackson, Mississippi; Jessica Leighton, PhD, MPH, New York City Department of Health & Mental Hygiene, New York, New York; Valarie Johnson, Urban Parent to Parent, Rochester, New York; Tracey Lynn, DVM, MPH**, Alaska Department of Health and Social Services, Anchorage, Alaska; Sally Odle, SafeHomes, Inc., Waterbury, Connecticut; George G. Rhoads, MD, MPH, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; Catherine M. Slota-Varma, MD, Pediatrician, Milwaukee, Wisconsin; Wayne R. Snodgrass, PhD, MD, University of Texas Medical Branch, Galveston, Texas; Kevin U. Stephens, Sr., MD, JD, New Orleans Department of Health, New Orleans, LA; Kimberly M. Thompson, ScD, Harvard School of Public Health, Boston, Massachusetts

*ACCLPP member until May 2004

**ACCLPP member until October 2004

Ex-Officio Members: Robert J. Roscoe, MS, Centers for Disease Control and Prevention; Jerry Zelinger, MD, Centers for Medicare and Medicaid Services; Walter Rogan, MD, National Institute for Occupational Safety and Health Sciences; John Borrazzo, PhD, U.S. Agency for International Development; Lori Saltzman, U.S. Consumer Product Safety Commission; David E. Jacobs, PhD, CIH, U.S. Department of Housing and Urban Development; Jacqueline E. Mosby, MPH, U.S. Environmental Protection Agency; Michael P. Bolger, PhD, U.S. Food and Drug Administration

Liaison Representatives: Anne M. Guthrie, MPH, Alliance for Healthy Homes; Jan Towers, PhD, American Academy of Nurse Practitioners; J. Routt Reigart, II, MD (1997-2004), American Academy of Pediatrics; George C. Rodgers, Jr., MD, PhD, American Association of Poison Control Centers; Steve M. Hays, CIH, PE, American Industrial Hygiene Association; Ben Gitterman, MD, American Public Health Association; Henry Bradford, Jr., PhD, Association of Public Health Laboratories; Ezatollah Keyvan-Larijani, MD, DrPH, Council of State and Territorial Epidemiologists; Pat McLaine, RN, MPH, National Center for Healthy Housing

Review of Evidence for Effects at BLLS <10 micrograms/dL Work Group: Michael L. Weitzman, MD (Chair) Center for Child Health Research, University of Rochester; Tom Matte, MD, MPH, National Center for Environmental Health, Centers for Disease Control and Prevention; David Homa, PhD, National Center for Environmental Health, Centers for Disease Control and Prevention; Jessica Sanford, PhD, Battelle Memorial Institute; Alan Pate, Battelle Memorial Institute; Joel Schwartz, PhD, Department of Environmental Health, Howard School of Public Health; David Bellinger, PhD, Neuroepidemiology Unit Children's Hospital, Harvard Medical School; David A. Savitz, PhD, Department of Epidemiology, University of North Carolina School of Public Health; Carla Campbell, MD, MS, Division of General Pediatrics, The Children's Hospital of Philadelphia; Patrick J. Parsons, PhD, Wadsworth Center for Laboratories and Research, New York State Department of Health; Betsy Lozoff, MD, Center for Human Growth and Development, University of Michigan; Kimberly Thompson, ScD, Department of Health Policy and Management, Harvard School of Public Health; Birt Harvey, MD, Pediatrician, Palo Alto, California

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the Centers for Disease Control and Prevention (CDC) Web site.

Print copies: Available from the Centers for Disease Control and Prevention, MMWR, Atlanta, GA 30333. Additional copies can be purchased from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325; (202) 783-3238.

AVAILABILITY OF COMPANION DOCUMENTS

The following is available:

  • Recommendations for blood lead screening of young children enrolled in Medicaid: targeting a group at high risk. MMWR Recomm Rep 2000 Dec 8;49(RR-14):1-13.

Electronic copies: Available from the Centers for Disease Control and Prevention Web site:

Print copies: Available from the Centers for Disease Control and Prevention, MMWR, Atlanta, GA 30333. Additional copies can be purchased from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402-9325; (202) 783-3238.

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on November 8, 2005.

COPYRIGHT STATEMENT

No copyright restrictions apply.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo